Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors.

@article{Lenihan2013OverviewAM,
  title={Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors.},
  author={Daniel J. Lenihan and Peter Russell Kowey},
  journal={The oncologist},
  year={2013},
  volume={18 8},
  pages={900-8}
}
BACKGROUND Small-molecule tyrosine kinase inhibitors (TKIs) may provide an effective therapeutic option in patients with hematologic malignancies and solid tumors. However, cardiovascular (CV) events, including hypertension, heart failure, left ventricular systolic dysfunction, and QT prolongation, have emerged as potential adverse events (AEs) with TKI therapy. PURPOSE We review what is known about the mechanism of action of CV AEs associated with TKI use and discuss therapeutic… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

Rationale for Cardio-Oncology Units.

Revista espanola de cardiologia • 2017
View 1 Excerpt

References

Publications referenced by this paper.

Similar Papers

Loading similar papers…